Europäische Union - Deutsch - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatid - diabetes mellitus, typ 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - lixisenatidum - solution pour injection - lixisenatidum 0.05 mg, glycerolum (85 per centum), natrii acetas trihydricus, methioninum, conserv.: metacresolum 2.7 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - antidiabetikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - lixisenatidum - solution pour injection - lixisenatidum 0.1 mg, glycerolum (85 per centum), natrii acetas trihydricus, methioninum, conserv.: metacresolum 2.7 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - antidiabetikum - synthetika